GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy

Jack T STAPLETON; Kathryn CHALONER; JINGYANG ZHANG; Donna KLINZMAN; Inara E SOUZA; JINHUA XIANG; Alan LANDAY; John FAHEY; Richard POLLARD; Ronald MITSUYASU

doi:10.1097/QAD.0b013e32831f1b00

Back

GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy

Journal article

Open access

Peer reviewed

GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy

Jack T STAPLETON, Kathryn CHALONER, JINGYANG ZHANG, Donna KLINZMAN, Inara E SOUZA, JINHUA XIANG, Alan LANDAY, John FAHEY, Richard POLLARD and Ronald MITSUYASU

AIDS (London), Vol.23(5), pp.605-610

2009

DOI: 10.1097/QAD.0b013e32831f1b00

PMCID: PMC2739595

PMID: 19194270

Files and links (1)

url

https://doi.org/10.1097/QAD.0b013e32831f1b00View

Published (Version of record) Open Access

Abstract

Objective: Interleukin-2 (IL-2) is a cytokine with multiple effects on lymphocytes including induction of CD4 T-cell proliferation. IL-2 administration has been shown to increase CD4 cell counts in HIV-infected people receiving antiretroviral therapy. GB virus C (GBV-C) is an apparently nonpathogenic flavivirus that replicates in CD4 T cells and inhibits HIV replication in vitro by mechanisms including downregulation of HIV entry coreceptors (CCR5 and CXCR4) and induction of chemokines (RANTES, MIP-1alpha, MIP-1 beta, and SDF-1). GBV-C replication is significantly inhibited in vitro by activation of primary CD4 cell cultures with IL-2 and phytohemagglutinin. We sought to determine if there is an interaction between GBV-C and IL-2 in vivo. Methods: GBV-C viremia status was characterized in 92 HIV-infected individuals participating in a randomized trial of IL-2 and antiretroviral therapy [AIDS Clinical Trials Group Study (ACTG) 328]. Changes in CD4 cell counts and HIV RNA levels in individuals assigned IL-2 were compared with those in individuals assigned antiretroviral therapy alone. Results: Individuals lacking GBV-C viremia had a significantly greater rise in CD4 cell count with IL-2, compared with GBV-C viremic individuals (by 511 cells/microl at week 84; interaction P = 0.02): GBV-C viremic individuals assigned IL-2 did not demonstrate a significant increase in CD4 cell count compared with individuals not assigned to receive IL-2 (95% CI for difference -255 to 397 cells/microl). Conclusion: GBV-C viremia was associated with a block in CD4 cell expansion following IL-2 therapy in the ACTG 328 study, and GBV-C status may be an important factor in IL-2 treatment response.

Infectious Diseases

Antiviral agents

Viral hepatitis

Pharmacology. Drug treatments

Viral diseases

Viral diseases of the lymphoid tissue and the blood. Aids

Biological and medical sciences

Medical sciences

Human viral diseases

Antibiotics. Antiinfectious agents. Antiparasitic agents

Details

Title: Subtitle: GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy
Creators: Jack T STAPLETON - Department of Internal Medicine, The University of Iowa, Iowa City, Iowa, United States
Kathryn CHALONER - Department of Biostatistics, The University of Iowa, Iowa City, Iowa, United States
JINGYANG ZHANG - Department of Biostatistics, The University of Iowa, Iowa City, Iowa, United States
Donna KLINZMAN - Iowa City VA Medical Center, The University of Iowa, Iowa City, Iowa, United States
Inara E SOUZA - Department of Internal Medicine, The University of Iowa, Iowa City, Iowa, United States
JINHUA XIANG - Department of Internal Medicine, The University of Iowa, Iowa City, Iowa, United States
Alan LANDAY - Rush Medical College, United States
John FAHEY - University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, United States
Richard POLLARD - University of California, Davis, School of Medicine, Sacramento, California, United States
Ronald MITSUYASU - University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, United States
Resource Type: Journal article
Publication Details: AIDS (London), Vol.23(5), pp.605-610
DOI: 10.1097/QAD.0b013e32831f1b00
PMID: 19194270
PMCID: PMC2739595
NLM abbreviation: AIDS
ISSN: 0269-9370
eISSN: 1473-5571
Publisher: Lippincott Williams & Wilkins
Language: English
Date published: 2009
Academic Unit: Microbiology and Immunology; Infectious Diseases; Internal Medicine
Record Identifier: 9984094522902771

Metrics

13 Record Views

31 Times Cited - Web of Science